Koselugo (selumetinib) is inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). MEK1/2 proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. Both MEK and ERK are critical components of the RAS-regulated RAF-MEK-ERK pathway, which is often activated in different types of cancers.
This report contains market size and forecasts of Selumetinib in global, including the following market information:
Global Selumetinib Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Selumetinib Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Selumetinib companies in 2021 (%)
The global Selumetinib market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
10 mg Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Selumetinib include AstraZeneca and Merck etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Selumetinib manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Selumetinib Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Selumetinib Market Segment Percentages, by Type, 2021 (%)
10 mg
25 mg
Global Selumetinib Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Selumetinib Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Selumetinib Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Selumetinib Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Selumetinib revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Selumetinib revenues share in global market, 2021 (%)
Key companies Selumetinib sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Selumetinib sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Merck